Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward (Q38184618)

30 August 2017

title

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward (English)

1 reference

30 August 2017

0 references

1 reference

1 reference

1

1 reference

30 August 2017

6

Giancarlo Logroscino

1 reference

30 August 2017

Bruno P Imbimbo

3

1 reference

ORCID Public Data File 2021

Vincenzo Solfrizzi

series ordinal

2

object named as

Vincenzo Solfrizzi

1 reference

30 August 2017

5

Andrea Santamato

1 reference

30 August 2017

4

Rosanna Tortelli

1 reference

30 August 2017

publication date

4 February 2014

1 reference

Expert Review of Clinical Immunology

30 August 2017

published in

1 reference

30 August 2017

volume

10

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

405-419

1 reference

Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators.

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Alzheimer's disease: clinical trials and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

The cell biology of Alzheimer's disease: uncovering the secrets of secretases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Interactions of Amyloidogenic Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Tau protein directly interacts with the amyloid beta-protein precursor: implications for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Beta-amyloid protein precursor and tau mRNA levels versus beta-amyloid plaque and neurofibrillary tangles in the aged human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Alzheimer's disease and the aging brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

A specific amyloid-beta protein assembly in the brain impairs memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

TAU Aggregation is a Therapeutic Target for Alzheimers Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Recent developments in tau-based therapeutics for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Therapeutic strategies for tau mediated neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Mechanisms of tau-induced neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

New and emerging treatments for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Immunotherapy in Alzheimer's disease: do we have all the pieces of the puzzle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Neuropathology of cognitively normal elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Intranasal inoculation with an adenovirus vaccine encoding ten repeats of Aβ3-10 reduces AD-like pathology and cognitive impairment in Tg-APPswe/PSEN1dE9 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Development of a new DNA vaccine for Alzheimer disease targeting a wide range of aβ species and amyloidogenic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Active vaccination with ankyrin G reduces β-amyloid pathology in APP transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Effect of rice-expressed amyloid β in the Tg2576 Alzheimer's disease transgenic mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Immunotherapy for Alzheimer's disease: hoops and hurdles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Solanezumab for the treatment of mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Decreased clearance of CNS beta-amyloid in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Gantenerumab for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Antibody-based therapy in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Intravenous immunoglobulin and Alzheimer's disease: what now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

beta-Amyloid precursor protein metabolism: focus on the functions and degradation of its intracellular domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

AICD nuclear signaling and its possible contribution to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Direct visualization of the gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein: association with Fe65 and translocation to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Nuclear signalling by membrane protein intracellular domains: the AICD enigma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

APP Intracellular Domain Impairs Adult Neurogenesis in Transgenic Mice by Inducing Neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

The physiology of the β-amyloid precursor protein intracellular domain AICD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

The gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Monoclonal antibodies that target pathological assemblies of Abeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

CR1 and the "vanishing amyloid" hypothesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Variant TREM2 as risk factor for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.883921

10.1586/1744666X.2014.883921

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference